Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery (CAPTRANE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03794388|
Recruitment Status : Recruiting
First Posted : January 7, 2019
Last Update Posted : May 14, 2019
Breast cancer is the most common cancer in women in Europe. Therefore, breast cancer has become a chronic disease and patients need to learn to live with it as well as with the adverse effects related to the disease itself or to the therapies used.
As noted in the third "Plan cancer", pain is a major criterion in the quality of life of patients treated for breast cancer.
Neuropathic pain was defined in 2011 by the international Association for the Study of Pain (I.A.S.P.) as the direct result of a lesion or disease affecting the somato-sensory system.
Surgical treatment is often the first treatment of breast cancer. It can be conservative by performing a partial mastectomy (lumpectomy or quadrantectomy) or non-preservative by total mastectomy.
Intercostobrachial neuralgia (NICB) or Post mastectomy painful Syndrome (MPRR) was first described by Wood in 1978 as "chronic pain beginning immediately or early after a mastectomy" Or a lumpectomy affecting the anterior thorax, armpit and/or arm in its upper half. These post-surgical pains are related to a lesion of the nerves in the breast area.
In particular, the intercostobrachial nerve can be severed, stretched or crushed during surgery.
Post-operative neuropathic pain in patients with breast cancer is underdiagnosed either by general practitioner or in a specialized environment.
The diagnosis of neuropathic pain is performed during examination and clinical examination. Several scales allow to detect neuropathic pain but only the DN4 is recognized to be the most specific and sensitive scale.
Patients do not always express this pain. They do not always reconcile with the surgery. Either because the pain occurs a long time after the surgery, or they find it normal to get hurt. These diagnostic difficulties cause a delay in setting up a suitable analgesic treatment.
However, neuropathic pain responds poorly to common analgesics. Diagnosis, evaluation and early management of neuropathic pain are a priority in order to avoid their chronicization, to improve the quality of life of patients with breast cancer and to enable them to return to work quickly.
We therefore assume that the diagnosis of early neuropathic pain at 2 months of surgery associated with initiation of appropriate topical treatment without the systemic effects of conventional oral treatments, would reduce the incidence of Chronic neuropathic pain 6 months after surgery.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Patient||Drug: Capsaicin Drug: Pregabalin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||772 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Multicenter, open, randomized study|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Multicentric, Open, Randomized Study Comparing Topical Treatment by Patch of Capsaicin to 8% (Qutenza) to Pregabalin Oral in the Early Treatment of Neuropathic Pain After Primary Surgery for Breast Cancer|
|Actual Study Start Date :||March 19, 2019|
|Estimated Primary Completion Date :||March 19, 2022|
|Estimated Study Completion Date :||March 19, 2023|
Experimental: Arm CAPSAICINE topical
Application of capsaicin patches at 8% on the painful area
1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later.
Application of capsaicin patches at 8% on painful area
Other Name: qutenza EU/1/09/524/001
Active Comparator: Arm PREGABALINE
Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.
An interval of 3 to 7 days must be observed between each dose increase.
Taking Pregabalin tablets
Other Name: Lyrica
- To show the noninferiority of early early medical treatment by topical treatment with capsaicin compared to oral treatment of pregabalin on the evolution of neuropathic pain after 2 months in patients who have undergone surgical excision of breast cancer [ Time Frame: 2 months ]The 11-point numerical scale (0-10) is collected at 2 months.
- To compare the efficacy of an early medical treatment with capsaicin topical treatment compared to oral treatment pregabalin on the evolution of neuropathic pain in patients who had undergone excision surgical breast cancer after 6 months of treatment [ Time Frame: 6 months ]The 11-point numerical scale of pain is also collected at the end of treatment
- To compare the functional change and quality of life perceived by patients after 2 and 6 months of treatment between the two arms: Questionnaire PGIC (patients' global impression of change) [ Time Frame: 6 months ]Questionnaire PGIC is administered to M4, M6 and at the end of treatment to measure the functional changes and quality of life changes experienced by the patient in the 2 treatment arms.
- To compare the functional change and quality of life perceived by patients after 2 and 6 months of treatment between the two arms [ Time Frame: 6 months ]Questionnaire QLQ-C30 (quality of life questionnaire) is administered to M4, M6 and at the end of treatment to measure the functional changes and quality of life changes experienced by the patient in the 2 treatment arms.
- To compare the functional change and quality of life perceived by patients after 2 and 6 months of treatment between the two arms [ Time Frame: 6 months ]Questionnaire EQ-5D is administered to M4, M6 and at the end of treatment to measure the functional changes and quality of life changes experienced by the patient in the 2 treatment arms.
- Regression of the painful area after 2 and 6 months of treatment between the two arms. [ Time Frame: 6 months ]The painful area is measured from pain mapping at baseline, and after 2 months and 6 months of treatment. It is measured by the area delimited by the contours of the painful surface (centralized reading).
- Tolerance of each type of treatment by collecting side effects in each treatment arm. [ Time Frame: 6 months ]The tolerance of the treatments will be measured by the number of patients having at least one adverse event of grade ≥ 2 according to the classification CTCAE v5.0.
- Proportion of patients for whom only 1 application has been sufficient. [ Time Frame: 6 months ]In the capsaicin arm, the number of total patches received by the patient during the 6 months will also be counted
- Impact of peri-surgical anxiety and depression on the development of neuropathic pain after surgery for breast cancer [ Time Frame: 49 months ]The HAD (Hospital anxiety and despression scale) questionnaire will be collected during the screening visit
- The incidence of NICBs 4 months after surgery for breast cancer [ Time Frame: 4 months ]The incidence of NICBs will be measured by the number of patients included in the study (DN4 +) compared to the number of patients screened before surgery
- The evolution of the weight between the two arms after 6 months of treatment. [ Time Frame: 6 months ]The weight is collected after 6 months of treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794388
|Contact: DENIS DUPOIRON, MD||+33 firstname.lastname@example.org|
|Contact: MARINE TIGREAT||+33 email@example.com|
|Institut de Cancerologie de L'Ouest||Recruiting|
|Angers, France, 49000|
|Contact: DENIS DUPOIRON, MD +33 241352700 ext 2873 firstname.lastname@example.org|
|Grenoble, France, 38700|
|Contact: Caroline MAINDET, MD Cmaindetdominici@chu-grenoble.fr|
|La Roche-sur-Yon, France, 85025|
|Contact: Yves-Marie PLUCHON, MD email@example.com|
|Centre Oscar Lambret||Recruiting|
|Lille, France, 59020|
|Contact: Abesse AHMEIDI, MD firstname.lastname@example.org|
|Hopital Saitn Vincent de Paul||Recruiting|
|Lille, France, 59020|
|Contact: Romain CHIQUET, MD email@example.com|
|Centre Leon Berard||Not yet recruiting|
|Lyon, France, 69008|
|Contact: Gisèle CHVETZOFF, MD Gisele.firstname.lastname@example.org|
|Nice, France, 06003|
|Contact: Emilie PIQUET, MD email@example.com|
|Institut Jean Godinot||Recruiting|
|Reims, France, 51100|
|Contact: Olivier DUBROEUCQ, MD Olivier.DUBROEUCQ@reims.unicancer.fr|
|Institut Curie||Not yet recruiting|
|Saint-Cloud, France, 92210|
|Contact: Marie PECHARD, MD firstname.lastname@example.org|
|Toulouse, France, 31052|
|Contact: Valérie MAURIES SAFFON, MD email@example.com|
|Valenciennes, France, 53322|
|Contact: Antoine LEMAIRE firstname.lastname@example.org|
|Study Director:||DENIS DUPOIRON, MD||Institut de Cancérologie de l'Ouest|